

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

PDMR Dealing / Grant of Share Options

23 October 2023 - Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform, announces that it has granted a total of 2,500,500 options over its ordinary shares of 1 pence each ("Ordinary Shares"), to Group employees, including certain directors and PDMRs of the Company, as outlined in the table below.

The options were granted under the Company's 2016 Employee Share Option Plan with an exercise price of 34p per share, being the closing share price on 19 October 2023, the day immediately preceding the grant of the options. Prior to the grant, Chief Financial Officer Paul Stockdale surrendered 50,000 share options originally awarded in 2018.

The newly-granted options will vest in three equal tranches on the first, second and third anniversaries of the date of grant. Vested options will remain exercisable up to and including the tenth anniversary of the date of grant.

Following this grant, the individuals referred to above hold options over Ordinary Shares and are interested in Ordinary Shares as follows:

| | New options granted | Total number of options over Ordinary Shares | Ordinary Shares held | |
|--|---------------------|--|----------------------|-----------------------------------|
| | | | Number | % of current issued share capital |
| Alexandre Akoulitchev, <i>Chief Scientific Officer</i> | 250,000 | 1,596,131 | 6,603,082 | 3.26% |
| Paul Stockdale, <i>Chief Financial Officer</i> | 250,000 | 1,050,000 | 331,818 | 0.23% |
| Matthew Wakefield, <i>Non Executive Chairman</i> | 150,000 | 400,000 | 1,022,727 | 0.70% |
| David Holbrook, <i>Non Executive Director</i> | 75,000 | 115,000 | - | - |
| David Blum, <i>SVP of Marketing</i> | 250,000 | 462,500 | 75,000 | 0.04% |
| Thomas Guiel, <i>Chief Operations Officer</i> | 250,000 | 650,000 | 365,000 | 0.25% |
| Ewan Hunter, <i>Chief Data Officer</i> | 250,000 | 750,000 | 136,363 | 0.09% |

The notifications below, made in accordance with the requirements of UK Market Abuse Regulation, provide further details:

| | | |
|----------|--|--|
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Alexandre Akoulitchev |
| 2 | Reason for the notification | |
| a) | Position/status | Director/PDMR |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Oxford BioDynamics Plc |
| b) | LEI | 2138005Y1TK25805U928 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each ISIN: GB00BD5H8572 |
| b) | Nature of the transaction | Grant of share options |
| c) | Price(s) and volume(s) | 250,000 ordinary shares at an exercise price of 34 pence per share |
| d) | Aggregated information | N/A |

| | | |
|----|--|-------------------------|
| d) | Aggregated information - Aggregated volume - Price | N/A |
| e) | Date of the transaction | 20 October 2023 |
| f) | Place of the transaction | Outside a trading venue |

| | | |
|----------|--|--|
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | David Blum |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification/ Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Oxford BioDynamics Plc |
| b) | LEI | 2138005Y1TK25805U928 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each ISIN: GB00BD5H8572 |
| b) | Nature of the transaction | Grant of share options |
| c) | Price(s) and volume(s) | 250,000 ordinary shares at an exercise price of 34 pence per share |
| d) | Aggregated information - Aggregated volume - Price | N/A |
| e) | Date of the transaction | 20 October 2023 |
| f) | Place of the transaction | Outside a trading venue |

| | | |
|----------|--|------------------------|
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Thomas Guiel |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification/ Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Oxford BioDynamics Plc |

| | | |
|----------|--|--|
| b) | LEI | 2138005Y1TK25805U928 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each ISIN: GB00BD5H8572 |
| b) | Nature of the transaction | Grant of share options |
| c) | Price(s) and volume(s) | 250,000 ordinary shares at an exercise price of 34 pence per share |
| d) | Aggregated information - Aggregated volume - Price | N/A |
| e) | Date of the transaction | 20 October 2023 |
| f) | Place of the transaction | Outside a trading venue |

| | | |
|----------|--|---|
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | David Holbrook |
| 2 | Reason for the notification | |
| a) | Position/status | Director/PDMR |
| b) | Initial notification/ Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Oxford BioDynamics Plc |
| b) | LEI | 2138005Y1TK25805U928 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each ISIN: GB00BD5H8572 |
| b) | Nature of the transaction | Grant of share options |
| c) | Price(s) and volume(s) | 75,000 ordinary shares at an exercise price of 34 pence per share |
| d) | Aggregated information - Aggregated volume - Price | N/A |
| e) | Date of the transaction | 20 October 2023 |
| f) | Place of the transaction | Outside a trading venue |

| | | |
|----------|--|--|
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Ewan Hunter |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification/ Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Oxford BioDynamics Plc |
| b) | LEI | 2138005Y1TK25805U928 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each ISIN: GB00BD5H8572 |
| b) | Nature of the transaction | Grant of share options |
| c) | Price(s) and volume(s) | 250,000 ordinary shares at an exercise price of 34 pence per share |
| d) | Aggregated information - Aggregated volume - Price | N/A |
| e) | Date of the transaction | 20 October 2023 |
| f) | Place of the transaction | Outside a trading venue |

| | | |
|----------|--|---|
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Paul Stockdale |
| 2 | Reason for the notification | |
| a) | Position/status | Director/PDMR |
| b) | Initial notification/ Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Oxford BioDynamics Plc |
| b) | LEI | 2138005Y1TK25805U928 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each ISIN: GB00BD5H8572 |
| b) | Nature of the transaction | Surrender and grant of share options |
| c) | Price(s) and volume(s) | Options over 50,000 ordinary shares at an exercise price of €1.70 per |

| | | |
|----|--|--|
| c) | Price(s) and volume(s) | Options over 50,000 ordinary shares at an exercise price of £1.70 per share cancelled Options over 250,000 ordinary shares at an exercise price of 34 pence per share granted |
| d) | Aggregated information - Aggregated volume - Price | N/A |
| e) | Date of the transaction | 19, 20 October 2023 |
| f) | Place of the transaction | Outside a trading venue |

| | | |
|----------|--|--|
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Matthew Wakefield |
| 2 | Reason for the notification | |
| a) | Position/status | Director/PDMR |
| b) | Initial notification/ Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Oxford BioDynamics Plc |
| b) | LEI | 2138005Y1TK25805U928 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each ISIN: GB00BD5H8572 |
| b) | Nature of the transaction | Grant of share options |
| c) | Price(s) and volume(s) | 150,000 ordinary shares at an exercise price of 34 pence per share |
| d) | Aggregated information - Aggregated volume - Price | N/A |
| e) | Date of the transaction | 20 October 2023 |
| f) | Place of the transaction | Outside a trading venue |

-Ends-

For further details please contact:

Jon Burrows, CEO
Paul Stockdale, CFO

Shore Capital - Nominated Adviser and Broker
Stephane Auton / Iain Sexton

Tel: +44 (0)20 7408 4090

Instinctif Partners
Melanie Toyne-Sewell / Rozi Morris
Adam Loudon / Jack Kincade

Tel: +44 (0)20 7457 2020
OxfordBioDynamics@instinctif.com

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship products are the [EpiSwitch® CiRT](#) (Checkpoint Inhibitor Response Test) and [EpiSwitch® PSE](#) (EpiSwitch Prostate Screening test) blood tests. CiRT is a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022. PSE is a blood test that boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer, which has been launched in the US and UK in September 2023.

In March 2021, the Company launched its first commercial prognostic test, [EpiSwitch® CST](#) (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, [EpiSwitch® Explorer Array Kit](#), which is available for purchase by the life science research community.

The Company's product portfolio is based on a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for the prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 15,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg and a clinical laboratory in Frederick, MD, USA, and a reference laboratory in Penang, Malaysia.

For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow OBD on [Twitter](#) (@OxBioDynamics) and [LinkedIn](#).

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford BioDynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 15,000 samples in 30 disease areas, and reduced to practice.

In addition to stratifying patients with respect to anticipated clinical outcomes, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBXLFLXBLBFBV